Callori Fred 4
4 · CATABASIS PHARMACEUTICALS INC · Filed Feb 3, 2021
Insider Transaction Report
Form 4
Callori Fred
Director
Transactions
- Award
Series X Convertible Preferred Stock
2021-02-01$3009.53/sh+1,617$4,866,410→ 30,920 total(indirect: By Perceptive Xontogeny Venture Fund, LP)→ Common Stock (1,617,000 underlying)
Footnotes (2)
- [F1]Upon stockholder approval of the conversion of Series X Convertible Preferred Stock into shares of common stock, each share of Series X Non-Voting Convertible Preferred Stock automatically converts into 1,000 shares of Common Stock, subject to certain limitations.
- [F2]On February 1, 2021, Issuer completed its private placement pursuant to that certain Stock Purchase Agreement dated January 27, 2021 (the "Private Placement"). In connection with the Private Placement, a limited partnership (the "Fund") in which the Reporting Person has an indirect pecuniary interest purchased shares of Series X Convertible Preferred Stock. The Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of his pecuniary interest therein.